<DOC>
	<DOCNO>NCT02908035</DOCNO>
	<brief_summary>This prospective , multi-center , randomize , dose escalation study document effect adventitial delivery temsirolimus ( Torisel ) revascularization lesion knee symptomatic patient critical limb ischemia ( CLI ) .</brief_summary>
	<brief_title>Temsirolimus Adventitial Delivery Improve Angiographic Outcomes Below Knee ( TANGO )</brief_title>
	<detailed_description>This prospective , multi-center , randomize , dose escalation study document effect adventitial delivery temsirolimus ( Torisel ) revascularization lesion knee symptomatic patient critical limb ischemia ( CLI ) . Up 60 patient ( 20 low-dose , 20 high-dose 20 control ) 15 site United States . This study ass safety effectiveness Bullfrog Micro-Infusion Device adventitial deposition temsirolimus reduce intimal hyperplasia , inflammatory marker composite safety endpoint patient clinical evidence chronic critical limb ischemia revascularization one angiographically significant lesion ( ) below-knee popliteal tibial vessel .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Screening Criteria : Age ≥18 year &lt; 90 year Patient inform nature study , agree participate sign IRB approve consent form Female patient childbearing potential negative pregnancy test ≤7 day procedure willing use highly effective method birth control ( See Section 12.2 ) one month precede 12 month follow study treatment Patient document chronic Critical Limb Ischemia ( CLI ) target limb distal segment ( P3 ) popliteal artery ankle joint prior study procedure Rutherford Category 3 , 4 5 Life expectancy &gt; 1 year Investigator 's opinion Angiographic Criteria : Target vessel ( ) diameter ≥2 mm ≤8 mm Single multiple atherosclerotic lesion ( ) ≥70 % least one belowknee popliteal tibial target vessel include tibioperoneal trunk total great 30 cm length ( great 5 cm length contiguous intervene normal artery ) , possible extension popliteal artery distal center knee joint space ( P3 segment ) Successful revascularization TL le 30 % residual stenosis , runoff foot direct inline flow foot wound , wound present baseline • Screening Criteria Patient already enrol another clinical study systemic drug therapy another device study complete primary endpoint Patient unwilling unlikely comply visit schedule Patients incapable provide consent and/or incapable understanding nature , significance implication clinical trial Patient already receive plan receive systemic immunotherapy , chemotherapy , steroid ( however , inhaled steroid asthma treatment topical steroid use allow ) Patient bilirubin level &gt; 1.5xULN Recent ( &lt; 30 day prior study procedure ) myocardial infarction Cerebrovascular accident &lt; 60 day prior study procedure Planned major ( ankle ) target limb amputation Active foot infection ; however , osteomyelitis toe mild cellulitis around perimeter gangrene small ulcer ( &lt; 25mm ) exclusion , osteomyelitis metatarsal proximal region would exclusionary Inability receive temsirolimus iodinate contrast medium due label contraindication know sensitivity reaction Estimated glomerular filtration rate ( eGFR , calculate serum creatinine use isotope dilution mass spectrometry ( IDMS ) traceable equation ) less 30 mL/min , except patient end stage renal disease chronic hemodialysis Stage 3 ( per SVS WIfI classification ) bad heel ulcer heel ulcer determine primarily neuropathic nature nonischemic origin Angiographic/Procedural Criteria Hemodynamically significant inflow lesion ( ≥50 % DS ) occlusion ipsilateral iliac , SFA , popliteal artery ( P1 P2 ) failure successfully treat obtain &lt; 30 % residual stenosis postrevascularization , bailout stenting need ( inflow lesion treat prior treat target lesion ) Target lesion length &gt; 30 cm measure proximal normal vessel distal normal vessel Total length lesion treat case ( include target lesion , inflow lesion , nontarget lesion ) &gt; 30 cm Use alternative therapy , e.g . radiation therapy , drugeluting stent ( DES ) drugeluting balloon/drugcoated balloon ( DEB/DCB ) part target lesion treatment previous 2 month within target lesion Previously implant stent TL ( ) Aneurysm target vessel Acute thrombus target limb Failure cross TL guide wire ; however , subintimal wire crossing allow Heavy eccentric concentric calcification target lesion , judgment investigator would prevent penetration MicroInfusion Device needle vessel wall</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>